Dataset Information


PROCARDIS Consortium

ABSTRACT: The PROCARDIS programme to identify susceptibility loci in precocious CAD, was initiated in October 1998 as a collaboration between the universities of Oxford and Munster, the Karolinska Institute, the Mario Negri Institute, Oxagen (a biotechnology company), and AstraZeneca (the pharmaceutical company). This consortium received support from a Concerted Action award of the 5th Framework Programme and 6th Framework Programme. We have a collection of 3,000 affected sibling pairs (ASPs) and families with precocious CAD (onset before the age of 65 years) and have applied genome-wide linkage mapping techniques by typing SNPs spaced throughout the genome. Thus the PROCARDIS programme has been designed to allow mapping of novel CAD susceptibility genes without being limited by current knowledge of disease mechanisms.

PROVIDER: EGAO00000000005 | EGA |


altmetric image


<h4>Background</h4>An increased level of Lp(a) lipoprotein has been identified as a risk factor for coronary artery disease that is highly heritable. The genetic determinants of the Lp(a) lipoprotein level and their relevance for the risk of coronary disease are incompletely understood.<h4>Methods</h4>We used a novel gene chip containing 48,742 single-nucleotide polymorphisms (SNPs) in 2100 candidate genes to test for associations in 3145 case subjects with coronary disease and 3352 control subj  ...[more]

Similar Datasets

| E-TABM-670 | BioStudies
| S-EPMC4259362 | BioStudies
2009-07-10 | E-TABM-670 | ArrayExpress
| S-EPMC1852708 | BioStudies
| S-EPMC3316968 | BioStudies
2018-01-01 | S-EPMC5855311 | BioStudies
| S-EPMC6865971 | BioStudies
| S-EPMC3679547 | BioStudies
| S-EPMC7511090 | BioStudies
| S-EPMC7496858 | BioStudies